GleamWall
中文EN

ELVN Enliven Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1672619 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.7%
TTM EPS YoY6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-16.8%
ROA-16.4%
ROIC (approx.)-19.4%
Asset turnover—

Leverage & solvency

Liabilities / assets2.3%
Debt / equity0.00x
Current ratio45.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$28.02M$29.00M$20.69M$21.25M$18.23M$21.49M$24.89M$20.72M
SG&A expense$8.02M$8.21M$7.14M$13.04M$6.87M$7.09M$6.80M$6.17M
Operating income-$36.05M-$37.21M-$27.82M-$34.28M-$25.10M-$28.58M-$31.69M-$26.90M
Income tax———$0$0$0—$0
Net income-$27.70M-$32.48M-$23.63M-$29.67M-$20.15M-$25.34M-$28.54M-$23.18M
EBITDA-$36.03M-$37.20M-$27.81M-$34.20M-$25.03M-$28.50M-$31.62M-$26.83M
EPS (basic)-0.36-0.49-0.38—-0.32-0.49-0.57—
EPS (diluted)-0.36-0.49-0.38—-0.32-0.49-0.57—
Weighted avg. shares (diluted)77.98M66.17M62.80M—62.09M52.11M50.05M—
Balance sheet
Cash & equivalents$151.67M$135.50M$132.18M$98.90M$101.73M$119.44M$101.70M$124.17M
Short-term investments$732.68M$759.65M$320.22M$363.73M$375.83M$371.07M$187.85M$189.32M
Current assets$894.76M$907.34M$463.14M$474.88M$482.68M$495.62M$294.32M$318.13M
PP&E, net$201,000$140,000$20,000$34,000$399,000$462,000$404,000$458,000
Total assets$897.23M$910.22M$464.85M$476.17M$490.88M$503.89M$302.57M$325.76M
Current liabilities$19.47M$14.16M$11.49M$16.57M$14.65M$15.21M$13.97M$15.91M
Total liabilities$20.28M$15.07M$11.49M$16.57M$14.75M$15.41M$14.27M$15.91M
Shareholders' equity$876.95M$895.15M$453.37M$459.60M$476.12M$488.47M$288.30M$309.85M
Shares outstanding73.56M73.25M60.89M59.44M59.26M59.23M49.04M48.94M
Cash flow statement
Operating cash flow-$12.55M-$18.53M-$19.29M-$15.84M-$13.28M-$17.06M-$24.13M-$17.20M
Capital expenditure$94,000$99,000$0$0-$1,000$139,000$20,000$0
Free cash flow-$12.65M-$18.63M-$19.29M-$15.84M-$13.28M-$17.20M-$24.15M-$17.20M
Investing cash flow$26.33M-$441.57M$42.53M$12.38M-$4.06M-$183.59M$1.43M$727,000
Financing cash flow$2.39M$463.42M$10.05M$623,000-$368,000$218.38M$234,000$39.97M
Depreciation & amortization$13,000$7,000$14,000$83,000$62,000$81,000$74,000$63,000
Stock-based compensation$8.06M$13.91M$7.40M$12.31M$7.18M$7.72M$6.80M$5.34M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.